Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An 8-Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI greater than or equal to 30) With Stage 2 Hypertension.

Next Previous
Trial Profile

An 8-Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI greater than or equal to 30) With Stage 2 Hypertension.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Mar 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aliskiren/hydrochlorothiazide (Primary) ; Ramipril (Primary)
  • Indications Essential hypertension; Hypertension
  • Focus Therapeutic Use
  • Acronyms ATTAIN
  • Sponsors Novartis

Most Recent Events

  • 01 May 2010 Results presented at 25th Annual Scientific Meeting of the American Society of Hypertension.
  • 20 May 2009 Actual patient number (386) added as reported by ClinicalTrials.gov.
  • 20 May 2009 Actual end date (1 May 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top